CCL

Összesen 48 találat.
#/oldal:
Részletezés:
Rendezés:

1.

001-es BibID:BIBFORM074271
035-os BibID:(WoS)000438781600007 (Scopus)85047721348
Első szerző:Agostini, Maura
Cím:A Pharmacogenetic Approach to the Treatment of Patients With PPARG Mutations / Maura Agostini, Erik Schoenmakers, Junaid Beig, Louise Fairall, Istvan Szatmari, Odelia Rajanayagam, Frederick W. Muskett, Claire Adams, A. David Marais, Stephen O'Rahilly, Robert K. Semple, Laszlo Nagy, Amit R. Majithia, John W. R. Schwabe, Dirk J. Blom, Rinki Murphy, Krishna Chatterjee, David B. Savage
Dátum:2018
ISSN:0012-1797
Megjegyzések:Loss-of-function mutations in PPARG cause familial partial lipodystrophy type 3 (FPLD3) and severe metabolic disease in many patients. Missense mutations in PPARG are present in ?1 in 500 people. Although mutations are often binarily classified as benign or deleterious, prospective functional classification of all missense PPARG variants suggests that their impact is graded. Furthermore, in testing novel mutations with both prototypic endogenous (e.g., prostaglandin J2 [PGJ2]) and synthetic ligands (thiazolidinediones, tyrosine agonists), we observed that synthetic agonists selectively rescue function of some peroxisome proliferator-activated receptor-γ (PPARγ) mutants. We report on patients with FPLD3 who harbor two such PPARγ mutations (R308P and A261E). Both PPARγ mutants exhibit negligible constitutive or PGJ2-induced transcriptional activity but respond readily to synthetic agonists in vitro, with structural modeling providing a basis for such differential ligand-dependent responsiveness. Concordant with this finding, dramatic clinical improvement was seen after pioglitazone treatment of a patient with R308P mutant PPARγ. A patient with A261E mutant PPARγ also responded beneficially to rosiglitazone, although cardiomyopathy precluded prolonged thiazolidinedione use. These observations indicate that detailed structural and functional classification can be used to inform therapeutic decisions in patients with PPARG mutations.
Tárgyszavak:Orvostudományok Elméleti orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Megjelenés:Diabetes. - 67 : 6 (2018), p. 1086-1092. -
További szerzők:Schoenmakers, Erik Beig, Junaid Fairall, Louise Szatmári István (1971-) (biológus) Rajanayagam, Odelia Muskett, Frederick W. Adams, Claire Marais, A. David O'Rahilly, Stephen Semple, Robert K. Nagy László (1966-) (molekuláris sejtbiológus, biokémikus) Majithia, Amit R. Schwabe, John W. R. Blom, Dirk J. Murphy, Rinki Chatterjee, Krishna Savage, David B.
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

2.

001-es BibID:BIBFORM069085
Első szerző:Amin, N. B.
Cím:Two dose-ranging studies with PF-04937319, a systemic partial activator of glucokinase, as add-on therapy to metformin in adults with type 2 diabetes / Amin N. B., Aggarwal N., Pall D., Paragh G., Denney W. S., Le V., Riggs M., Calle R. A.
Dátum:2015
ISSN:1462-8902
Megjegyzések:AIM:To assess the efficacy and safety of a range of doses of a systemic, partial, glucokinase activator, PF-04937319, as add-on therapy to metformin, in patients with type 2 diabetes mellitus (T2DM).METHODS:Patients were randomized to once-daily PF-04937319 doses of 10, 50, 100?mg, or matching placebo (Study B1621002); or PF-04937319 doses of 3, 20, 50, 100?mg, or matching placebo (Study B1621007). Titrated glimepiride (Study B1621002) or sitagliptin (Study B1621007) were included in a double-dummy manner. The primary measure was change from baseline in glycated haemoglobin (HbA1c) at week 12. Key secondary measures included other glycaemic variables and safety and tolerability.RESULTS:In the 639 patients randomized, the minimally efficacious PF-04937319 dose was identified as 50?mg once daily. At the highest PF-04937319 dose tested (100?mg), on average, a clinically significant reduction in HbA1c [-4.94 or -5.11?mmol/mol (-0.45 or -0.47%), placebo-adjusted], which was similar to that achieved with sitagliptin [-4.69?mmol/mol (-0.43%)] but lower than that achieved with titrated glimepiride [-9.07?mmol/mol (-0.83%)], was observed. At this dose, the effect on fasting plasma glucose was not consistent between the two studies (Study B1621002 vs Study B1621007: placebo-adjusted mean change of -0.83 vs +0.50?mmol/l). PF-04937319 was well tolerated at doses up to 100?mg. Hypoglycaemia was reported in 2.5% of patients (on placebo), 5.1% of patients (on PF-04937319 100?mg), 1.8% of patients (on sitagliptin) and 34.4% of patients (on titrated glimepiride).CONCLUSIONS:In patients on metformin monotherapy, the addition of a 100-mg dose of PF-04937319 improved glycaemic control and was well tolerated.TRIAL REGISTRATION:ClinicalTrials.gov NCT01475461 NCT01517373.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
PF-04937319
glycaemic control
type 2 diabetes
Megjelenés:Diabetes Obesity & Metabolism 17 : 8 (2015), p. 751-759. -
További szerzők:Aggarwal, N. Páll Dénes (1967-) (belgyógyász, kardiológus) Paragh György (1953-) (belgyógyász) Denney, W. S. Le, V. Riggs, M. Calle, R. A.
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

3.

001-es BibID:BIBFORM005896
Első szerző:Bajnok László (belgyógyász)
Cím:Relationship of serum resistin level of traits of metabolic syndrome and serum paraoxonase 1 activity in a population with a broad range of body mass index / Bajnok L., Seres I., Varga Zs., Jeges S., Peti A., Karányi Zs., Juhász A., Csongrádi É., Mezősi E., Nagy E. V., Paragh Gy.
Dátum:2008
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Megjelenés:Experimental and Clinical Endocrinology and Diabetes. - 116 : 10 (2008), p. 592-599. -
További szerzők:Seres Ildikó (1954-) (biokémikus) Varga Zsuzsa (1951-) (biokémikus, nephrológus) Jeges Sára Peti Attila Karányi Zsolt (1961-) (biostatisztikus, bioinformatikus) Juhász Attila (1970-) (szakorvos, klinikai mikrobiológus) Csongrádi Éva (1969-) (szakorvos) Mezősi Emese Nagy Endre V. (1957-) (belgyógyász, endokrinológus) Paragh György (1953-) (belgyógyász)
Internet cím:elektronikus változat
DOI
Borító:

4.

001-es BibID:BIBFORM015579
Első szerző:Balogh Zoltán (belgyógyász, gasztroenterológus, diabetológus)
Cím:Gemfibrozil increases paraoxonase activity in type 2 diabetic patients : a new hypothesis of beneficial action of fibrates? / Balogh Z., Seres I., Harangi M., Kovács P., Kakuk G., Paragh G.
Dátum:2001
ISSN:1262-3636
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
egyetemen (Magyarországon) készült közlemény
Megjelenés:Diabetes & Metabolism 27 : 5Pt1 (2001), p. 604-610. -
További szerzők:Seres Ildikó (1954-) (biokémikus) Harangi Mariann (1974-) (belgyógyász, endokrinológus) Kovács Péter (1947-) (belgyógyász, kardiológus, klinikai farmakológus) Kakuk György (1938-2018) (belgyógyász) Paragh György (1953-) (belgyógyász)
Internet cím:Intézményi repozitóriumban (DEA) tárolt változat
Borító:

5.

001-es BibID:BIBFORM041585
Első szerző:Barkai László (gyermekgyógyász)
Cím:Microvascular complications in children and adolescents with type 1 diabetes / L. Barkai, I. Gurieva, A. Striban, S. Tesfaye, L. Czupryniak, B. N. Mankovsky, V. Spallone, I. A. Veresiu, O. Schnell, P. Kempler
Dátum:2012
Megjegyzések:The increasing incidence of type 1 diabetes in children and adolescents emphasizes the need to focus on potential diabetic complications as well. These complications may also occur subclinically and increase at the onset of puberty. In type 1 diabetes, the absence of microvascular complications such as nephropathy, retinopathy, and neuropathy is associated with a life expectancy comperable with that of the general population. Therefore, successful screening and prevention of microvascular complications play a key role in managing younger diabetic patients. The frequency of screening for nephropathy, retinopathy, and neuropathy has been summarized in guidelines, and also depends on age, diabetes duration, and individual risk factors such as family predisposition, puberty, and elevated blood pressure. Optimized glycaemic control plays a key role in efficiency reducing the risk and progression of all microvascular complications. Current consensus recommendations for symptomatic pharmacological treatment of painful diabetic peripheral neuropathy include anticonvulsants; studies have also shown that the thiamine prodrug benfotiamine (S-benzoylthiamine-O-monophosphate) may prevent the formation of advanced glycation end products (AEGs), and may therefore improve early nerve dysfunction in adolescents with type 1 diabetes. The aim of this paper was to review the epidemiology, screening and prevention of microvascular complications from type 1 diabetes in younger patients.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
diabetes in the young
nephropathy
retinopathy
neuropathy
benfotiamine
külföldön készült közlemény
Megjelenés:Diabetes, Stoffwechsel und Herz. - 21 : 5 (2012), p. 309-315. -
További szerzők:Gurieva, I. Striban, A. Tesfaye, S. Czupryniak, Leszek Mankovsky, Boris N. Spallone, V. Veresiu, I. A. Schnell, Oliver Kempler Péter (1954-) (belgyógyász, diabetológus)
Internet cím:Intézményi repozitóriumban (DEA) tárolt változat
Borító:

6.

001-es BibID:BIBFORM099715
Első szerző:Bekele, Bayu Begashaw (PhD hallgató)
Cím:Public health interventions on prescription redemptions and secondary medication adherence among type 2 diabetes patients : systematic review and meta-analysis of randomized controlled trials / Bayu Begashaw Bekele, Biruk Bogale, Samuel Negash, Melkamsew Tesfaye, Dawit Getachew, Fekede Weldekidan, Tewodros Yosef
Dátum:2021
ISSN:2251-6581
Megjegyzések:Background Despite the inadequate flling of prescriptions among chronic care patients has been a problem, little is known about the intervention efect on it. Objective The aim of this systematic review and meta-analysis (SRMA) was to investigate the efectiveness of various public health interventions on primary and secondary medication adherence among T2DM patients. Methods Searching was done from the major databases; Cochrane Library, Medline/PubMed, EBSCOhost, and SCOPUS. A hand search was made to fnd grey works of literature. Articles focused on interventions to enhance primary and secondary medication among type 2 diabetes mellitus patients were included. After screening and checking eligibility, the methodological quality was assessed. Secondary medication adherence was synthesized descriptively due to measurement and defnition variations across studies. Finally, a meta-analysis was made using the fxed efects model for primary medication adherence. Results 3992 studies were screened for both primary and secondary medication adherences. Among these, 24 studies were included in the analysis for primary (5) and secondary (19) medication adherence. Pooled relative medication redemption diference was RD=8% (95% CI: 6?11%) among the intervention groups. Age, intervention, provider setting, and IDF region were determinant factors of primary medication adherence. About two-thirds of the studies revealed that interventions were efective in improving secondary medication adherence. Conclusion Both primary and secondary medications were enhanced by a variety of public health interventions for patients worldwide. However, there is a scarcity of studies on primary medication adherence globally, and in resource-limited settings for the type of adherences.
Tárgyszavak:Orvostudományok Egészségtudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
T2DM
Medication adherence
Intervention
meta-analysis
RCT
Megjelenés:Journal of Diabetes and Metabolic Disorders. - 20 (2021), p. 1933-1956. -
További szerzők:Bogale, Biruk Negash, Samuel Tesfaye, Melkamsew Getachew, Dawit Weldekidan, Fekede Yosef, Tewodros
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

7.

001-es BibID:BIBFORM099684
035-os BibID:(WoS)000624905300052 (Scopus)85099630518
Első szerző:Bekele, Bayu Begashaw (PhD hallgató)
Cím:Diabetes mellitus, metabolic syndrome, and physical activity among Ethiopians : a systematic review / Bayu Begashaw Bekele, Dilshad Manzar, Mazen Alqahtani, Seithikurippu R. Pandi-Perumal
Dátum:2021
ISSN:1871-4021 1878-0334
Megjegyzések:Background and aims:The incidence of diabetes mellitus (DM) is increasing worldwide, and there isgrowing appreciation for the impact of limited physical activity on the disease. This study aimed todetermine whether the current research on DM in Ethiopia has sufficiently identified and focused on theimportance of limited physical activity according to the Global Physical Activity Questionnaire (GPAQ) inthe disease etiology.Methods:This was a systematic review, performed according to the PRISMA checklist. We searchedprimary studies of diabetes, diabetes-related complications, determinants, and magnitude of relatedmorbidities in Ethiopia in PubMed, Medline, and ISI Web of Science databases. Reviews, editorial com-munications, reports, and letters were excluded.Results:Among 363 articles that were identified from all databases, 28 were included. It was found that39% of the studies measured and included limited physical activity as a predisposing lifestyle factor indiabetes, while 17.86% either did not report or did not include this variable at all. Although 42.86% of thestudies identified limited physical activity as an etiological factor in diabetes, it was not measured ac-cording to the GPAQ guidelines.Conclusions:These data suggest that Ethiopian researchers do not give sufficient attention to the role ofphysical activity and its definition per GPAQ as a preventative factor for reducing the severity of diabetessymptoms. We suggest that physical activity research and promotion should be advocated in Ethiopia,and that researchers should seek advice on how to re-frame their work in the future.
Tárgyszavak:Orvostudományok Egészségtudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Megjelenés:Diabetes and Metabolic Syndrome: Clinical Research and Reviews. - 15 : 1 (2021), p. 257-265. -
További szerzők:Manzar, Dilshad Alqahtani, Mazen Pandi-Perumal, Seithikurippu R.
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

8.

001-es BibID:BIBFORM099706
035-os BibID:(WoS)000624905300040 (Scopus)85099072716
Első szerző:Bekele, Bayu Begashaw (PhD hallgató)
Cím:Effect of diabetes self-management education (DSME) on glycated hemoglobin (HbA1c) level among patients with T2DM : systematic review and meta-analysis of randomized controlled trials / Bayu Begashaw Bekele, Samuel Negash, Biruk Bogale, Melkamsew Tesfaye, Dawit Getachew, Fekede Weldekidan, Behailu Balcha
Dátum:2021
ISSN:1871-4021 1878-0334
Megjegyzések:Background and aims:Type 2 Diabetes mellitus (T2DM) has been a global public health issue causing inphysical,financial and psychosocial crises. The aim of this systematic review and meta-analysis (SRMA)was to evaluate the Diabetes Self-Management Education or Support (DSME/S) on glycosylated hemo-globin (HbA1c) among T2DM patients.Methods:This SRMA was made according to preferred reporting Items for systematic review and Meta-analysis (PRISMA) guidelines. The relevant articles were searched from four databases: Cochrane Library,MEDLINE (EBSCOhost), MEDLINE/PubMed and SCOPUS. Quality assessment was carried out. Pooledstandard mean difference in HbA1c were calculated to obtain the effect size with random effectassumption. Subgroup analysis was conducted for assessing heterogeneity among the studies.Results:A total of 1312 studies were identified from databases. Among these 25 studies met inclusioncriteria. From these 20 were included in the meta-analysis. In meta-analysis a pooled standard meandifference in HbA1c was 0.604 (95% confidence interval? 0.854 -0.353, I2?90.3, p<0.001). Insubgroup analysis a significant reduction was seen among studies with less than four months, uppermiddle followed by lower middle income countries (LMICs), Western Pacific (WP) followed by MiddleEastern and Northern African (MENA) regions with moderate to substantial heterogeneity.Conclusion:However, there is paucity of studies in underdeveloped countries. Therefore, further studiesvalidated to these contexts are needed to evaluate the DSME effectiveness.Trial registration: PROSPERO database CRD42020124236
Tárgyszavak:Orvostudományok Egészségtudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
DSME
Glycemic control
Meta-analysis
Randomized control trial
T2DM
Megjelenés:Diabetes and Metabolic Syndrome: Clinical Research and Reviews. - 15 : 1 (2021), p. 177-185. -
További szerzők:Negash, Samuel Bogale, Biruk Tesfaye, Melkamsew Getachew, Dawit Weldekidan, Fekede Balcha, Behailu
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

9.

001-es BibID:BIBFORM073014
Első szerző:Berta Eszter (belgyógyász)
Cím:Early stage Graves' disease is uniformly accompanied by orbital immune activity even in patients who fail to develop orbithopathy during follow-up / Eszter Berta, Miklós Bodor, László Galuska, György Paragh, Annamária Erdei, Annamária Gazdag, Bernadett Ujhelyi, Ervin Berényi, Mónika Katkó, Andrea Gazsó, Endre V. Nagy
Dátum:2018
ISSN:0947-7349
Megjegyzések:Purpose. Graves' orbitopathy (GO) is a complication of Graves' disease (GD), the development of which cannot be predicted at the time of diagnosis of GD. Our aims were (i) to test if orbital 99mTc-labelled diethylenetriamine pentaacetic acid single-photon emission computer tomography (DTPA SPECT) can predict development of GO later during the course of the disease and (ii) to study whether orbital immune activity can be detected in GD patients who do not develop GO during follow-up.Methods. Fifty-four orbits of 27 patients with newly diagnosed GD were entered into the case-control study. Individuals showing signs of GO at enrolment were excluded. During the two-year follow up, eye signs were recorded every 3 months. Orbital DTPA uptakes on SPECT images were measured when entering the study and at the end of the follow-up period, or when clinical signs of GO developed, whichever occurred first.Results. During thefollow up, 6 patients (22%) were diagnosed with GO. There was no significant difference between the initial DTPA uptakes of the patients with or without later developing GO (10.45?1.72 MBq/cm vs. 9.18?1.18 MBq/cm3 respectively). However, the DTPA uptakes of both GD groups (ie. with and without GO) were higher than that of the control group (7.45?1.36 MBq/cm3, p<0.05).Conclusions. We have shown that GD is accompanied by moderate orbital immune activity in GD patients without GO, irrespective of later development of GO. Why this orbital autoimmunity remains subclinical in the majority of the cases, and progresses into clinically detectable GO in others, remains unclear.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
pajzsmirigy
endokrin orbitopathia
Megjelenés:Experimental And Clinical Endocrinology & Diabetes. - 126 : 10 (2018), p. 628-631. -
További szerzők:Bodor Miklós (1969-) (belgyógyász, endokrinológus) Galuska László (1946-) (belgyógyász, izotópdiagnoszta) Paragh György (1953-) (belgyógyász) Erdei Annamária (1976-) (belgyógyász) Gazdag Annamária (1979-) (belgyógyász) Ujhelyi Bernadett (1981-) (szemész) Berényi Ervin (1964-) (radiológus) Katkó Mónika (1980-) (biológus) Gazsó Andrea Nagy Endre V. (1957-) (belgyógyász, endokrinológus)
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

10.

001-es BibID:BIBFORM097032
035-os BibID:(cikkazonosító)744516
Első szerző:Carinci, Fabrizio
Cím:Making Use of Comparable Health Data to Improve Quality of Care and Outcomes in Diabetes : the EUBIROD Review of Diabetes Registries and Data Sources in Europe / Fabrizio Carinci, Iztok Stotl, Scott G. Cunningham, Tamara Poljicanin, Ivan Pristas, Vivie Traynor, George Olympios, Vasos Scoutellas, Joseph Azzopardi, Kris Doggen, János Sándor, Róza Ádány, Karianne F. Lvaas, Przemka Jarosz-Chobot, Joanna Polanska, Simion Pruna, Simon de Lusignan, Marcello Monesi, Paolo Di Bartolo, Christa Scheidt-Nave, Christin Heidemann, Inbar Zucker, Anita Maurina, Jana Lepiksone, Peter Rossing, Martti Arffman, Ilmo Keskimäki, Soffia Gudbjornsdottir, Concetta Tania Di Iorio, Elisabeth Dupont, Stella de Sabata, Niek Klazinga, Massimo Massi Benedetti
Dátum:2021
Megjegyzések:Background: Registries and data sources contain information that can be used on an ongoing basis to improve quality of care and outcomes of people with diabetes. As a specific task of the EU Bridge Health project, we carried out a survey of diabetes-related data sources in Europe. Objectives: We aimed to report on the organization of different sources of diabetes information, including their governance, information infrastructure and dissemination strategies for quality control, service planning, public health, policy and research. Methods: Survey using a structured questionnaire to collect targeted data from a network of collaborating institutions managing registries and data sources in 17 countries in the year 2017. Results: The 18 data sources participating in the study were most frequently academic centres (44.4%), national (72.2%), targeting all types of diabetes (61.1%) covering no more than 10% of the target population (44.4%). Although population-based in over a quarter of cases (27.8%), sources relied predominantly on provider-based datasets (38.5%), fewer using administrative data (16.6%). Data collection was continuous in the majority of cases (61.1%), but 50% could not perform data linkage. Public reports were more frequent (72.2%) as well as quality reports (77.8%), but one third did not provide feedback to policy and only half published ten or more peer reviewed papers during the last 5 years. Conclusions: The heterogeneous implementation of diabetes registries and data sources hampers the comparability of quality and outcomes across Europe. Best practices exist but need to be shared more effectively to accelerate progress and deliver equitable results for people with diabetes.
Tárgyszavak:Orvostudományok Egészségtudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
diabetes
diabetes registries
quality of care
performance indicators
risk adjustment
health information
Megjelenés:Frontiers in Clinical Diabetes and Healthcare. - 2 (2021), p. 1-14. -
További szerzők:Stotl, Iztok Cunningham, Scott G. Poljicanin, Tamara Pristas, Ivan Traynor, Vivie Olympios, George Scoutellas, Vasos Azzopardi, Joseph Doggen, Kris Sándor János (1966-) (orvos-epidemiológus) Ádány Róza (1952-) (megelőző orvostan és népegészségtan szakorvos) Lvaas, Karianne F. Jarosz-Chobot, Przemyslawa Polanska, Joanna Pruna, Simion de Lusignan, Simon Monesi, Marcello Di Bartolo, Paolo Scheidt-Nave, Christa Heidemann, Christin Zucker, Inbar Maurina, Anita Lepiksone, Jana Rossing, Peter Arffman, Martti Keskimäki, Ilmo Gudbjornsdottir, Soffia Di Iorio, Concetta Tania Dupont, Elisabeth de Sabata, Stella Klazinga, Niek Benedetti, Massimo Massi
Pályázati támogatás:DG-SANCO in the EU project Bridge Health (GA 664691)
Egyéb
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

11.

001-es BibID:BIBFORM041484
Első szerző:Ceriello, Antonio
Cím:Diabetes as a case study of chronic disease management with a personalized approach : the role of a structured feedback loop / Antonio Ceriello, László Barkai, Jens Sandahl Christiansen, Leszek Czupryniak, Ramon Gomis, Kari Harno, Bernhard Kulzer, Johnny Ludvigsson, Zuzana Némethyová, David Owens, Oliver Schnell, Tsvetalina Tankova, Marja-Riitta Taskinen, Bruno Vergèsm, Raimund Weitgasser, Johan Wens
Dátum:2012
ISSN:0168-8227
Megjegyzések:As non-communicable or chronic diseases are a growing threat to human health and economic growth, political stakeholders are aiming to identify options for improved response to the challenges of prevention and management of non-communicable diseases. This paper is intended to contribute ideas on personalized chronic disease management which are based on experience with one major chronic disease, namely diabetes mellitus. Diabetes provides a pertinent case of chronic disease management with a particular focus on patient self-management. Despite advances in diabetes therapy, many people with diabetes still fail to achieve treatment targets thus remaining at risk of complications. Personalizing the management of diabetes according to the patient's individual profile can help in improving therapy adherence and treatment outcomes. This paper suggests using a six-step cycle for personalized diabetes (self-)management and collaborative use of structured blood glucose data. E-health solutions can be used to improve process efficiencies and allow remote access. Decision support tools and algorithms can help doctors in making therapeutic decisions based on individual patient profiles. Available evidence about the effectiveness of the cycle's constituting elements justifies expectations that the diabetes management cycle as a whole can generate medical and conomic benefit.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
külföldön készült közlemény
Megjelenés:Diabetes Research And Clinical Practice. - 98 : 1 (2012), p. 5-10. -
További szerzők:Christiansen, Jens Sandahl Czupryniak, Leszek Gomis, Ramon Harno, Kari Kulzer, Bernhard Ludvigsson, Johnny Némethyová, Zuzana Owens, David Schnell, Oliver Tankova, Tsvetalina Taskinen, Marja-Riitta Vergèsm, Bruno Weitgasser, Raimund Wens, Johan Barkai László (1958-) (gyermekgyógyász)
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

12.

001-es BibID:BIBFORM120116
035-os BibID:(Scopus)85170690960 (WoS)001066356100001
Első szerző:Chatterjee, Tulika
Cím:Type 1 diabetes, COVID-19 vaccines and short-term safety : subgroup analysis from the global COVAD study / Tulika Chatterjee, Naveen Ravichandran, Narmadha Nair, Abraham Edgar Gracia-Ramos, Bhupen Barman, Parikshit Sen, Mrudula Joshi, Sreoshy Saha, Arvind Nune, Arun Kumar R. Pande, Tsvetelina Velikova, Ioannis Parodis, Ai Lyn Tan, Samuel Katsuyuki Shinjo, Hiya Boro, Vikas Agarwal, Rohit Aggarwal, Latika Gupta, COVAD Study Group
Dátum:2023
ISSN:2040-1116 2040-1124
Megjegyzések:Aims/introduction: Coronavirus disease 2019 (COVID-19) vaccinations have been proven to be generally safe in healthy populations. However, the data on vaccine safety in patients with type 1 diabetes are scarce. This study aimed to evaluate the frequency and severity of short-term (<7-day) adverse vaccination events (AEs) and their risk factors among type 1 diabetes patients. Materials and methods: This study analyzed data from the COVID-19 vaccination in Autoimmune Diseases (COVAD) survey database (May to December 2021; 110 collaborators, 94 countries), comparing <7-day COVID-19 vaccine AE among type 1 diabetes patients and healthy controls (HCs). Descriptive statistics; propensity score matching (1:4) using the variables age, sex and ethnicity; and multivariate analyses were carried out. Results: This study analyzed 5,480 completed survey responses. Of all responses, 5,408 were HCs, 72 were type 1 diabetes patients (43 females, 48.0% white European ancestry) and Pfizer was the most administered vaccine (39%). A total of 4,052 (73.9%) respondents had received two vaccine doses. Patients with type 1 diabetes had a comparable risk of injection site pain, minor and major vaccine AEs, as well as associated hospitalizations to HCs. However, type 1 diabetes patients had a higher risk of severe rashes (3% vs 0.4%, OR 8.0, 95% confidence interval 1.7-36), P = 0.007), although reassuringly, these were rare (n = 2 among type 1 diabetes patients). Conclusions: COVID-19 vaccination was safe and well tolerated in patients with type 1 diabetes with similar AE profiles compared with HCs, although severe rashes were more common in type 1 diabetes patients.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
COVID-19
Type-1 diabetes mellitus
Vaccine
Megjelenés:Journal of Diabetes Investigation. - 15 : 1 (2023), p. 131-138. -
További szerzők:Ravichandran, Naveen Nair, Narmadha Gracia-Ramos, Abraham Edgar Barman, Bhupen Sen, Parikshit Joshi, Mrudula Saha, Sreoshy Nune, Arvind Pande, Arunkumar R. Velikova, Tsvetelina Parodis, Ioannis Tan, Ai Lyn Shinjo, Samuel Katsuyuki Boro, Hiya Agarwal, Vikas Aggarwal, Rohit Gupta, Latika Nagy-Vincze Melinda (1985-) (orvos) COVAD Study Group
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Rekordok letöltése1 2 3 4 
Corvina könyvtári katalógus v8.2.27 © 2023 Monguz kft. Minden jog fenntartva.